nplate header

Article

body { color: #000000; /* color: #002F65; */ background-color:#f5f5f5; } table { background-color:#FFFFFF; text-align:left; font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; } p, div { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; } h3 { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight:bold; } a { color:#3e7ebc; } a:hover { text-decoration:underline } p { margin:10px 0px 10px 0px; } ol, ul{ list-style: none; padding-left:0px; } .header-link { font-size: 13px; font-weight: bold; color: #C41230; text-decoration:none } .mainbody { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; padding: 10px 30px 10px 30px; } .otherbody { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; color: #000000; } .blue-link { color: #002F65; text-decoration: underline; } .blue-bold-link { color: #002F65; text-decoration: underline; font-size: 13px; font-weight: bold; } .red-header { font-size: 13px; font-weight: bold; color: #C41230; } .smbullet-item { background-image:url(sm-bullet.gif); } .bullet-item { background-color: transparent; background-image: url("http://imaging.ubmmedica.com/all/cn/infocenter/chronic-itp/bullet.gif"); background-repeat: no-repeat; background-attachment: scroll; background-position: 0pt 2px; padding-top: 0pt; padding-right: 0pt; padding-bottom: 15px; padding-left: 20px; margin-bottom: 12px; margin-left:25px } li { list-style:disc; padding-top: 0pt; padding-right: 0pt; padding-bottom: 5px; padding-left: 5px; margin-bottom: 0px; margin-left:25px } #bulletItems li { list-style: none; background-color: transparent; background-image: url("http://imaging.ubmmedica.com/all/cn/infocenter/chronic-itp/bullet.gif"); background-repeat: no-repeat; background-attachment: scroll; background-position: 0pt 5px; padding-top: 0pt; padding-right: 0pt; padding-bottom: 5px; padding-left: 20px; margin-bottom: 0px; margin-left:15px } #bulletItems p, .tan { color: #E8D4A3 } .resBox { width: 250px; border-left-width-value: 1px; border-left-style-value: solid; border-left-color-value: #d3d3d3; border-right-width-value: 1px; border-right-style-value: solid; border-right-color-value: #d3d3d3; padding-top: 0px; padding-right: 10px; padding-bottom: 0px; padding-left: 10px; text-align: left; word-wrap: break-word; } #wrapper { width:100%; padding:0px; margin:0px; text-align:center; } /************************ ***** DO NOT EDIT ******/#container { /*width: 80%;*/ width: 300px; margin-right: auto; margin-left: auto; text-align: left; background-color: #FFFFFF;}/* Bar Graphs */.graph { width: 280px; position: relative; right: 16px;}.bar-title { position: relative; float: left; width: 140px; line-height: 20px; margin-right: 12px; font-weight: bold; text-align: right; color: #C41230;}.bar-container { position: relative; float: left; width: 120px; height: 10px; margin: 0px 0px 15px;}.bar-container div { background-color:#c61130; height: 20px;}.bar-container strong { position: absolute; right: 0; top: 0px; overflow: hidden;}#poll-results p { clear: both; text-align: center;}#poll-container { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size:11px; background: #ffffff url(/blank-theme/images/custom/poll-bg-top.png) 0 0 no-repeat; padding: 16px 24px 16px 16px; line-height: 14px;}#poll-bottom { height: 12px; width: 300px; background: #ffffff url(/blank-theme/images/custom/poll-bg-bottom.png) bottom left no-repeat;}#poll-container input { margin: 8px 4px 0;}#poll-container label { color: #C41230; font-weight: bold;}#poll-container p { color: black; line-height: 20px; padding-top: 5px; padding-right: 5px; padding-bottom: 5px; padding-left: 5px;}#poll-container h3 { margin: 8px;}input#pollbutton { width: 78px; height: 30px; float: right; margin: 10px -4px -10px 0; border: 0 none; cursor: pointer; display: inline; background: transparent url(/blank-theme/images/custom/poll-button.png) top left no-repeat;}/***************************** END DO NOT EDIT *****/

CancerNetwork Home

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.